DGNews
Patients with choroidal neovascularisation secondary to age-related macular degeneration (AMD) who are treated with bevacizumab plus photodynamic therapy (PDT) and triamcinolone require fewer treatments over the course of a year than patients who receive bevacizumab alone, researchers stated here at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting.